FDA Awards Fast-Track Voucher for Kids' Rare Disease Drug
Published Date: 8/28/2025
Notice
Summary
The FDA just gave a special fast-track ticket called a priority review voucher to Chimerix, Inc. for their rare pediatric disease drug, MODESYO (dordaviprone), approved on August 6, 2025. This voucher helps speed up future drug reviews, benefiting companies working on rare kids' diseases and potentially getting treatments to patients faster. It’s a big win for rare disease drug developers and could impact how quickly new medicines reach the market.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Faster Reviews Could Reach Patients Sooner
The FDA says the priority review voucher helps speed up future drug reviews and could help get treatments for rare pediatric diseases to patients faster. The voucher was awarded for MODESYO (dordaviprone), approved August 6, 2025.
Priority Review Voucher Awarded to Company
The FDA issued a priority review voucher to Chimerix, Inc. for their rare pediatric disease product MODESYO (dordaviprone), which was approved on August 6, 2025. The voucher is an FDA-authorized tool that helps the sponsor speed up a future drug review.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-16514, Patient-Focused Drug Development: Workshop #2 To Discuss Methodologic and Other Challenges Related to Patient Experience Data; Public Workshop; Request for Comments
The FDA is hosting a fun and important workshop to tackle tricky questions about how to collect and use patient experience data when developing new medicines. This event helps patients, drug makers, and doctors work together to make treatments better and more patient-friendly. If you care about medicine that fits real people’s needs, this is your chance to join the conversation and shape the future!
Next: 2025-16516, In the Matter of Martina Juanita Gil, 2721 E. Caldwell Street, Phoenix, AZ 85042; Order Denying Export Privileges
Martina Juanita Gil from Phoenix got caught smuggling thousands of bullets from the U.S. to Mexico and was sentenced to over a year in prison plus supervised release. Because of this, her right to export goods is blocked for five years starting from her conviction date, and any export licenses she had are canceled. This means she can’t legally send stuff out of the country for a while, impacting her business activities.